Navigation Links
Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
Date:9/21/2007

istory of hepatitis, alcoholism, or liver cirrhosis may exacerbate underlying hepatic insufficiency. Caution in patients with impaired hepatic function.

Concurrent radiotherapy (given together or <7 days apart): Gemcitabine has radiosensitising activity and significant toxicity may occur, particularly with large volumes of radiotherapy. It is feasible to administer gemcitabine at lower doses than 1,000mg/meter squared with concurrent radiotherapy with predictable toxicity (see SPC).

Sequential radiotherapy (given >7 days apart): Enhanced toxicity has not occurred when gemcitabine was started after the resolution of acute radiation effects or at least one week after radiation. Enhanced toxicity from radiation therapy following gemcitabine exposure has not occurred.

Precautions

Usage in pregnancy or lactation: Avoid in pregnant or breast-feeding women, since safety has not been established. Experimental animal studies have shown reproductive toxicity.

Patients should be cautioned against driving or operating machinery until they are sure they do not become somnolent.

Adverse Reactions

Haematological: Very common: Anaemia, leucopenia, neutropenia, and thrombocytopenia. Common: Febrile neutropenia. Very rare: Thrombocythaemia.

Hepatobiliary: Very common: Elevation of liver transaminases (AST, ALT) and alkaline phosphatase. Common: Increased bilirubin. Very rare: Serious hepatotoxicity, including liver failure and death, in patients receiving gemcitabine alone or in combination with other potentially hepatotoxic drugs. Rare: Increased gamma-glutamyl transferase (GGT).

Gastro-intestinal: Very common: Nausea or vomiting, which require therapy in about 20% of patients and is rarely dose-limiting. Common: Diarrhoea, oral toxicity (mainly soreness and erythema), and constipation.

Renal: Very common: Proteinuria and haematuria, rarely clinically significant. Rare: Haemolytic uraemic syndrome and renal failure of unkno
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer Treatment
2. Making Science Personal: Lilly Oncology to Unveil 76 Studies at ASCO 2007
3. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Malvern initiates European user group meetings for chemical imaging
9. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
10. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
11. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015 Research and Markets ... of the "Lab Accessories Market by ... Station) & End User (OEM/Biotechnology & Pharmaceutical ... 2020" report to their offering. ... expected to reach $504.7 million by 2020 ...
(Date:4/24/2015)... Company, Inc. (NYSE: LCI ) today announced that ... facility to $120 million from $50 million.  The amended ... company to increase borrowings by a total of up ... commitments from existing lenders or new lending institutions.  The ... 2018.   "The amended credit facility, together ...
(Date:4/23/2015)... CHICAGO, Ill. , April 24, 2015  AbbVie ... Food and Drug Administration (FDA) has accepted its New ... company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, ... for the treatment of adults with chronic genotype 4 ... regimen is the first all-oral, interferon-free therapy being evaluated ...
Breaking Medicine Technology:Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 2Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 3Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
(Date:4/24/2015)... The first step to transforming one’s ... For meditation and yoga teacher Stine Koppernæs, meditation and ... tools that allow her to experience more peace and ... a teacher since 2006, and through the years she ... being. , “I love sharing this way of finding ...
(Date:4/24/2015)... Carinsurancequotesinfo.com has released a new blog ... to qualify for auto insurance as a ... auto insurance online, without having to follow a special ... parents can reduce their auto insurance expenses. The tips ... explained. , Clients can now visit an insurance ...
(Date:4/24/2015)... Integrative Therapeutics has introduced two new supplements ... , A unique combination of herbs and nutrients, ... Complex apart from other antioxidant supplements. This formula ... antioxidation versus the use of single or sequential ... Resveratrol, Alpha-Glycosyl Isoquercitrin, and Coenzyme Q10 with Setria® ...
(Date:4/24/2015)... Orlando, Fla. (PRWEB) April 24, 2015 ... extraordinary healer” were among the ways Denise Weiner described ... Angeles, who cared for her daughter, Alexa, during her ... radiation, brain resections, a bone marrow transplant and numerous ... the house to visit Alexa when she was not ...
(Date:4/24/2015)... 2015 Insuranceautoquote.info has released a new ... premiums . , Lowering auto insurance prices is ... simply find better offers for their financial budget. Comparing ... does not require any registration. , Comparing quotes ... are multiple agencies that sell coverage and this means ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Discounts for Single Parents - How to Qualify for Low Rates 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 3Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 4Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 2Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 3Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 4Health News:Car Insurance Quotes Can Help Drivers Lower Their Premiums 2
... June 23, 2009 With millions of people in the ... and our Canadian neighbors doing likewise for their July 1 ... shows of the future likely to ignite a smile on ... is quietly making its way toward the sky. ...
... HIV/AIDS Atlas , , WASHINGTON, June 22 ... HIV/AIDS Atlas ( http://www.MapHIV.org ) that highlights the impact ... States. The Atlas makes information on HIV/AIDS prevalence ... time, painting a comprehensive picture of the varying intensity ...
... Quality Forum Launches First U.S. HIV/AIDS Atlas , , ... launched a groundbreaking HIV/AIDS Atlas ( http://www.MapHIV.org ... in communities across the United States. The Atlas makes ... for the first time, painting a comprehensive picture of the ...
... Economy! It,s the Perfect Time for Fitness! , , LOS ... or stair climber in the park or along the beach. Now ... putting the traditional fitness equipment on wheels, but with a unique ... Pumgo Fitness Scooter, a new concept of fitness, will be introduced ...
... Biomodels CRO expertise in $1 billion market for cancer ... , , WATERTOWN, Mass., June 22 Biomodels ... care, today announced that its customized research program allowed ... attain Food and Drug Administration (FDA) approval for Phase ...
... in the Bone Graft Market , , MOUNTAIN VIEW, ... bone graft market, Frost & Sullivan recognizes Bone Solutions, Inc. ... Technology Leadership of the Year for its development of OsteoCrete(TM). ... and tendons to bone and bone-to-bone. On May 21, ...
Cached Medicine News:Health News:'Green' fireworks may brighten eco-friendly 4th of July displays in future 2Health News:MapHIV.org Shows Six Counties in Louisiana Seriously Impacted by AIDS 2Health News:MapHIV.org Shows Six Counties in Louisiana Seriously Impacted by AIDS 3Health News:MapHIV.org Shows California's San Francisco County Seriously Impacted by HIV 2Health News:MapHIV.org Shows California's San Francisco County Seriously Impacted by HIV 3Health News:Pumgo Fitness Scooter Will Highlight Venice Beach This Summer 2Health News:Biomodels' Oral Mucositis Expertise Speeds FDA Approval for ActoGeniX's Phase 1b Trial of AGO13 in Cancer Patients 2Health News:Frost & Sullivan Selects Bone Solutions for Technology Leadership of the Year Award 2Health News:Frost & Sullivan Selects Bone Solutions for Technology Leadership of the Year Award 3Health News:Frost & Sullivan Selects Bone Solutions for Technology Leadership of the Year Award 4
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... "three-in-one Microkeratome for traditional Lasik, Epi-Lasik and ... world of rapidly changing technologies and applications ... is and remains a proven value, offering ... needs and allows them to stay abreast ...
... individual components for individual indications. XCaliber covers ... of an innovative composite plastic material, XCaliber ... lighter. This means it's easier to handle, ... the patient. ,Come pre-assembled, packaged sterile, and ...
Medicine Products: